TrialClinical cancer research : an official journal of the American Association for Cancer Research2021

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.

Gang An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.